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Vascular smooth muscle cell proliferation mayoccur in response to endothelial
cell injury and is thought to play a major role in the genesis of the atheromatous
lesion (1) . Aside from the stimulatory effect of several smooth muscle cell
mitogens such as those derivedfrom platelets, endothelial cells, and macrophages
(2-4), smooth muscle cell proliferation can also be markedly inhibited by several
effectors released from arterial cells, among which are the heparinoid glycos-
aminoglycans (5) . Heparin has an antiproliferative effect that appears to be
independent of its anticoagulant activity (5, 6) ; and, from in vitro structure-
function studies (6), it is now apparent that heparin requires O-sulfation and N-
substitution with dodecasaccharides to show maximum inhibitory activity . Also,
confluent bovine endothelial cells generate a heparinase-sensitive material that
can inhibit smooth muscle cell proliferation (7) that hasbeen shown tobe released
by platelet-derived endoglycosidases that can cleave heparin and heparan sulfate
(8).
It is now recognized that heparin interacts with multiple proteins, including
antithrombin III (9), platelet factor 4 (10), fibrinogen (11), fibronectin (11),
albumin (9), thrombospondin (12), and heparin cofactor II (13) . A specific
interaction takes place with histidine-rich glycoprotein (HRGP), both in purified
systems and in plasma, with consequent neutralization of heparin anticoagulant
activity (14) . However, the role of HRGP in the modulation of arterial cell
proliferation remains undefined . We report herein studies that have examined
the effect of HRGP and other known heparin-binding proteins on the antipro-
liferative activity of heparin on cultured bovine arterial smooth muscle cells .
Materials and Methods
Materials .
￿
Porcine intestinal heparin was obtained from Elkins-Sinn, Inc. (Cherry Hill,
NJ) . Fatty acid-free albumin and fibrinogen were purchased from Sigma Chemical Co .
(St . Louis, MO). DME and heat-inactivated FCS were obtained from Gibco Laboratories
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(Grand Island, NY). Purified fibronectin was kindly supplied by Dr. Domenick Falcone
(Cornell University Medical College).
Cell Culture.
￿
Cells were cultured at 37'C in a humidified, flowing COQ incubator. All
media contained 4 mM glutamine, 100 ILg/ml penicillin, 100 ug/ml streptomycin, 5 JLg/ml
amphotericin. Bovine smooth muscle cells were grown in DME containing 10% FCS.
Isolation and Culture ofSmooth Muscle Cells.
￿
Smooth muscle cells were obtained from
adult bovine aortas by a modification of the explant technique of Ross (15). Cells were
harvested as previously described (15). Cells were subpassaged up to three times after
primary culture before the initiation of the experiments.
Assay of Cell Proliferation.
￿
Smooth muscle cells harvested by trypsin treatment from
semiconfluent cultures (15) were plated into 24-well tissue culture plates (Linbro Chemical
Co., Hamden, CT; Flow Laboratories, Inc., McLean, VA) at an initial density of 5-7 x
10' cells/well in growth medium. 24 h later, the medium was removed and replaced with
the control or test medium at 1 ml/well. Cells were harvested at 1 and 6-7 d after
replacement with control or test medium. Cells were not fed during the experiment after
the initial medium change. Cells were harvested (15) and counted in a Coulter counter in
duplicate. Cultures were routinely examined to assure complete removal of cells from the
plates after trypsinization and the absence of cellular debris, which is indicative, in part,
of cell lysis. We also routinely performed trypsn-blue exclusion tests to assess cell viability
after treatment of cell cultures. Cell viability was consistently >95%.
Control cultures, after attachment for 24 h, were placed in DME plus 10% FCS.
Experimental cell cultures were exposed to heparin alone and to varying concentrations
of HRGP, fibrinogen, fibronectin, or albumin in the presence and absence of heparin in
1 ml DME plus 10% FCS. Preliminary experiments were performed using varying doses
of heparin (0 .1-100 kg/ml). We demonstrated a dose-related inhibition ofsmooth muscle
cell proliferation at day 7 by the addition of heparin (data not shown). A single heparin
dose (50 tcg/ml) was chosen for all subsequent studies because of consistent inhibition at
this dose. Elkins-Sinn porcine intestinal heparin was chosen after comparison of several
other sources. These other sources of heparin demonstrated inconsistent antiproliferative
activity. At each dose level, eight separate analyses were done at each time point.
Histidine-rich Glycoprotein Isolation and Characterization. HRGP from fresh human
plasma was purified by the procedure of Morgan (16). Pancreatic trypsin inhibitor (2
ug/ml; Worthington Biochemical Corp., Freehold, NJ), as well as the serine protease
inhibitors, p-nitrophenyl-p'-guanidino benzoate HCl and PMSF (final concentration 10-5
M; Sigma Chemical Co., St. Louis, MO), were added to the plasma and to all buffers
throughout the purification procedure to prevent proteolysis of HRGP.
Results
Heparin Effect on Bovine Smooth Muscle Cell Proliferation. Bovine arterial
smooth muscle cells incubated with control media, showed typical spindle ap-
pearance. In contrast, cells grown in the presence of heparin (50 hg/ml) appeared
less dense, with areas which had more sparse, non-confluent cell growth . Cell
proliferation was inhibited 51% to 68% in the presence of heparin compared to
control cell growth at seven days. Cell viability did not appear to be influenced
by the presence of heparin.
Effect o,fHRGP on Heparin Antiproliferative Activity.
￿
Smooth muscle cells were
plated at sparse density as above . At 24 h, cells were washed and medium
containing 10 ;ig/ml or 50 ug/ml of HRGP in the presence and absence of
heparin (50 Pg/ml) and heparin alone (50 Aig/ml), were added to the wells. The
cells were incubated and cell counts were obtained on days 1 and 7 . The inhibition
of smooth muscle cell growth noted at day 7 in the presence of heparin was
reversed when 50 wg/ml HRGP was added (Fig. 1). Cell counts at day 7
demonstrated a progressive reversal of heparin inhibition with HRGP. Cells910
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FIGURE 1.
￿
Effect ofHRGP on bovine smooth muscle cell proliferation . Cells in culture were
exposed to : DME(control), 50 Ecg Elkins-Sinn porcine intestinal heparin (H), 10 and50 ag/ml
concentration of human HRGP, or a mixture of heparin and HRGP (H +HRGP). At days 1
and 7, cells were harvested by trypsinization and counted in a Coulter counter in duplicate .
Eight separate experiments were done at each time point. Bars indicateSEM .
0
N
N
V
50
250
200
150
100
50
Day I
￿
Day 7
1
￿
I
￿
I
￿
I
￿
I
￿
I
￿
I
Coned H
￿
HRGP HRGP H.
￿
M .
￿
conhol H
￿
HRGP HRGP H .
￿
H .
10
￿
50 HRGP HRGP
￿
10
￿
50 HRGP HRGP
10 50
￿
10 50
Treatment (,cg/ml)
Day7
CM1 .1 H FN FN FN N . H .
￿
Co~ M FN FN FN N. H.
110 220440 F11
￿
FN
￿
110 220440 FN
￿
FN
110 220
￿
110 220
Treatment (Pq/ml)
FIGURE 2 .
￿
Effect of fibrinogen (FN) on smooth muscle cell proliferation . Cells in culture
were grown with medium alone, with heparin (H), or with human fibrinogen (110, 220 Ecg/ml)
in the presence or absence of heparin. Cells were counted at 1 and 7 d . Eight separate
experiments were done at each time point. Bars indicateSEM .
incubated in the presence of HRGP alone showed no difference in cell prolifer-
ation compared with control cells at day 7 (Fig . 1) . Additional controls consisted
of cells exposed to fibrinogen, fibronectin, or albumin. There was no reversal of
the heparin antiproliferative effect when fibrinogen (Fig . 2), albumin (Fig . 3), or
fibronectin (data not shown) were used .
Discussion
We investigated the effects of various serum proteins on heparin inhibition of
vascular smooth muscle cell proliferation . The rationale was based on previousM
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FIGURE 3.
￿
Effect of human albumin (ALB) on smooth muscle cell proliferation. Cells were
grown with medium alone, heparin (H), or with human albumin (1, 10, 100 Ag/ml), with or
withoutheparin. Cells were counted at 1 and 7 d. Eight separate experiments were done at
each time point. Bars indicate SEM.
studies demonstrating that heparin is a potent inhibitor of smooth muscle cell
proliferation (5-8). This antiproliferative effect is independent of heparin anti-
coagulant activity (5), and is associated with a reduction in DNA, RNA, and
protein synthesis (17). This effect may be mediated in vivo by platelet endogly-
cosidase-releasable, heparinase-sensitive heparinoids that may be generated by
the endothelium (8).
In this study, we were able to confirm the findings of others (7, 8) that there
is a dose-related inhibition of bovine arterial smooth muscle cells by heparin.
This effect appeared reproducible and consistent with only Elkins-Sinn heparin,
reflecting the probable heterogeneity of biological activity in heparins from
various commercial sources recently noted by Castellot et al. (18). Inhibition of
cell growth was best attained at 50 /Ag/ml heparin and ranged from 51 to 68%.
This higher dose requirement, in contrast with the amount used in other studies
(6), may reflect the use of non-growth arrested cells. Castellot et al. (7) have
shown that quiescent, growth-arrested cellsare more sensitive togrowth medium
containing heparin than exponentially growing cells.
HRGP wasevaluated for possible effectson heparin's antiproliferativeactivity.
HRGP has diverse biological effects, but the exact function ofthis glycoprotein
remains unclear. We were able to demonstrate a dose-related reversal of the
heparin antiproliferative effect with HRGP. Using 50 Ag HRGP, the heparin
effect was abolished (Fig. 1). This effect was noted despite substoichiometric
concentrations of HRGP. This may reflect the known heterogeneity ofheparin
fragments in unfractionated commercial heparin, with only a portion of the
heparin present possessing antiproliferative activity or the need for a threshold
level of free heparin to induce inhibition. Castellot et al. (6) have noted a dose-
related effect with heparin that is maximal with 12-residue fragments or larger
butpresent at the hexasaccharide level. HRGP could alter heparin activity by an
independent, direct proliferative effect on the smooth muscle cell itself or by91 2
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interfering directly or indirectly with heparin by high-affinity binding with the
polysaccharide (14) . A direct mitogenic effect appears unlikely since HRGP alone
did not increase smooth muscle cell proliferation (Fig. 1). HRGP may also
interfere with the heparin inhibitory effect by binding and blocking the heparin
binding site on the smooth muscle cell, which has now been putatively identified
(19). In contrast to HRGP, fibrinogen (Fig. 2), albumin (Fig. 3), or fibronectin
(data not shown) did not appear to have an affect on cell proliferation or on
heparin inhibition of cell growth. Similarly, antithrombin III and a crude
preparation of platelet factor 4 do not reverse the inhibitory effect of heparin
on smooth muscle cell mitogenesis, as shown by Hoover et al. (20), suggesting
that a HRGP-heparin-smooth muscle cell interaction is specific.
Arterial injury induced by de-endothelialization results in a multicellular
response with the influx of platelets, macrophages, and lymphocytes, and the
probable release of numerous soluble mediators. HRGP, in addition to its
presence in plasma, is present in both macrophages and platelets. The ability of
HRGP to specifically influence the inhibitory effect of heparin on smooth muscle
cell growth may reflect the complex regulation of this cell population within the
injured, atheromatous vessel wall, permitting transient unrestrained cell growth
for vessel repair.
Summary
Histidine-rich glycoprotein (HRGP), an a-glycoprotein in human plasma that
is also present in platelets and macrophages, binds heparin with high affinity and
neutralizes its anticoagulant activity. We now report that HRGP specifically
inhibits the antiproliferative effect of heparin on arterial smooth muscle cells
while other heparinoid-binding proteins do not influence mitogenesis. The
multicellular inflammatory response to endothelial injury characterized, in part,
by the influx of platelets and macrophages, may be associatedwith HRGP release
into the arterial microenvironment. This release of HRGP may allow smooth
muscle cell proliferation and atherogenesis by inhibiting the action ofendothelial
cell-derived heparinoid substances.
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